Predicting Survival Outcomes for Patients with Ovarian Cancer Using National Cancer Registry Data from Taiwan: A Retrospective Cohort Study

被引:0
|
作者
Chattopadhyay, Amrita [1 ]
Wu, Ya-Ting [1 ]
Chan, Han-Ching [1 ]
Kang, Yi-Ting [1 ]
Chiang, Ying-Cheng [2 ,3 ,4 ]
Chiang, Chun-Ju [1 ,5 ]
Lee, Wen-Chung [1 ,5 ,6 ]
Lu, Tzu-Pin [1 ,6 ,7 ]
机构
[1] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Coll Publ Hlth, Dept Publ Hlth, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Obstet & Gynecol, Hsinchu, Taiwan
[5] Taiwan Canc Registry, Taipei, Taiwan
[6] Natl Taiwan Univ, Inst Hlth Data Analyt & Stat, Coll Publ Hlth, Dept Publ Hlth, Taipei, Taiwan
[7] Natl Taiwan Univ, Populat Hlth Res Ctr, Taipei, Taiwan
来源
WOMENS HEALTH REPORTS | 2025年 / 6卷 / 01期
关键词
Epithelial ovarian cancer; Taiwan Cancer Registry (TCR); Surveillance Epidemiology and End Results registry (SEER); survival prediction; racial differences; PROGNOSTIC MODEL; PROTEIN; HE-4; SURGERY; MARKER; TRENDS; WOMEN;
D O I
10.1089/whr.2024.0166
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Ovarian cancer is one of the top seven causes of cancer deaths. Incidence of ovarian cancer varies by ethnicity, where Asian women demonstrate lower incidence rates than non-Hispanic Blacks and Whites. Survival prediction models for ovarian cancer have been developed for Caucasians and Black populations using national databases; however, whether these models work for Asians is unclear. Therefore, a retrospective cohort study was conducted to develop survival prediction models for patients with epithelial ovarian cancer from a Taiwan Cancer Registry (TCR) who underwent de-bulking and chemotherapy, with the aim to identify variables that can predict prognosis accurately. Patients diagnosed with OC from TCR were included. Method: Two prognostic models (M1 and M2) were developed: M1 utilized clinical variables only, M2 additionally included cancer-specific variables with the aim to improve the accuracy. All methods were repeated independently for patients with only serous ovarian cancer. All findings for model M1 were validated among Black, White, and Asian populations from Surveillance, Epidemiology, and End Results (SEER) database and 10-fold internal cross-validations. Due to absence of cancer-specific site variables in SEER, model M2 was only internally validated. Cox-proportional hazards regression analysis was performed and a stepwise strategy with Akaike-information criterion was used to select appropriate variables as predictors to develop both M1 and M2. Results: The c-index values of both models were >0.7 in both TCR and SEER populations for epithelial ovarian cancer. Calibration analysis demonstrated good prediction performance with the proportional difference between predicted and observed survival to be <5%. The performance was similar for the subset of patients with serous epithelial ovarian cancer. Notably, no significant racial differences were observed. Conclusion: The prognostic models proposed in this study can potentially be used for identifying patients, especially from Taiwan, at higher risk of ovarian cancer mortality early on, leading to improved prognosis, through shared decision-making between physicians and patients.
引用
收藏
页码:90 / 101
页数:12
相关论文
共 50 条
  • [21] Beta blocker use and ovarian cancer survival: A retrospective cohort study
    Eskander, R.
    Randall, L.
    Bessonova, L.
    Ward, K.
    Culver, H. Anton
    Harrison, T.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S111 - S111
  • [22] SURVIVAL OUTCOMES IN PATIENTS WITH COLORECTAL CANCER IN SWEDEN - A POPULATION-BASED RETROSPECTIVE REGISTRY STUDY
    Pasquali, L.
    Schain, F.
    VALUE IN HEALTH, 2020, 23 : S482 - S482
  • [23] SURVIVAL OF PATIENTS WITH BRAIN METASTASES FROM OVARIAN CANCER: RETROSPECTIVE MONOCENTRIC STUDY
    Trukhan, Hanna
    Skachkova, Valeria
    Ramanovich, Volha
    Mavrichev, Sergey
    Dalamanavs, Alena
    Brashko, Darya
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A290 - A291
  • [24] Maximal Effort Cytoreduction in Epithelial Ovarian Cancer: Perioperative Complications and Survival Outcomes from a Retrospective Cohort
    Haidopoulos, Dimitrios
    Pergialiotis, Vasilios
    Zachariou, Eleftherios
    Sapantzoglou, Ioakim
    Thomakos, Nikolaos
    Stamatakis, Emmanouil
    Alexakis, Nikolaos
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [25] Staging the cancer ecosystem: Survival data from a registry study of patients with active cancer.
    Cunningham, James R.
    Rittenbach, Jon
    Dodd, Cheryl
    Clemens, Mitch
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] The incidence and survival of Kaposi sarcoma using national cancer registry data
    Quaresma, Catarina
    Lapin, Agnieszka
    Vernon, Sally
    Tan, Agnieszka
    Venables, Zoe C.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [27] Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea
    Ha, Hyeong In
    Kim, Ji Hyun
    Lim, Jiwon
    Song, Yong Jung
    Won, Young-Joo
    Lim, Myong Cheol
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (01)
  • [28] Survival Analysis in Patients with Laryngeal Cancer: A Retrospective Cohort Study
    Molina-Fernandez, Elena
    Palacios-Garcia, Jose M.
    Moreno-Luna, Ramon
    Herrero-Salado, Tomas
    Ventura-Diaz, Julio
    Sanchez-Gomez, Serafin
    Vilches-Arenas, Angel
    LIFE-BASEL, 2023, 13 (02):
  • [29] Conditional relative survival of patients with endometrial cancer: a Korean National Cancer Registry study
    Shin, Dong Wook
    Jung, Kyu-Won
    Ha, Johyun
    Bae, Jaeman
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 33 (02)
  • [30] PREDICTING ONCOLOGIC SURVIVAL OUTCOMES USING MACHINE LEARNING AND LARGE-SCALE REGISTRY DATA THE BC CANCER REGISTRY EXPERIENCE
    Zhao, Rachel
    Kim, Melodie
    Marwaha, Arshdeep
    Stubbs, Terry
    Sandhu, Prableen
    Narinesingh, Dylan
    Badragan, Iulian
    Proulx, Ryan
    Krauze, Andra
    RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S56 - S56